...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Oncology Research >Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution
【24h】

Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution

机译：Nimotuzumab的长期使用与强度调制的放射治疗和化疗治疗局部晚期鼻咽癌：单一机构的经验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In this retrospective review of a single institution's experience, the efficacy and safety of the long-term use of nimotuzumab in combination with intensity-modulated radiotherapy (IMRT) and chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma (NPC) were studied. Between August 2008 and March 2014, 39 newly diagnosed patients with stages DI-IV NPC were treated with IMRT, chemotherapy, and nimotuzumab. Twenty patients were diagnosed with stage III (51.3%), 14 with stage IVA (35.9%), and 5 with stage IVB (12.8%) disease. All patients received at least one cycle of cisplatin-based induction chemotherapy followed by IMRT and more than nine cycles of nimotuzumab at 2(X) mg/week. Acute and late radiation-related toxicities were graded according to the Acute and Late Radiation Morbidity Scoring Criteria of the Radiation Therapy Oncology Group. Accumulated survival was calculated according to the Kaplan-Meier method. The log-rank test was used to compare survival differences. With a median follow-up of 46 months (range. 22-86 months), the estimated 3-year local recurrence-free, regional recurrence-free, distant metastasis-free, progression failure-free, and overall survival rates were 92.1%, 89.7%, 82.5%, 77.6%, and 86.8%, respectively. Univariate analysis showed that clinical stage and the cycle of induction chemotherapy were related with prognosis. The median cycle for the addition of nimotuzumab was 12 weeks. Grade 3 radiation-induced mucositis was observed in 15.8% of the treated patients. No skin rash or infusion reaction was observed, which is distinctly different from what was reported in patients treated with nimotuzumab. The major toxicities observed were grades I-II mucositis and leukocytopenia. Long-term use of nimotuzumab plus IMRT showed promising outcomes in terms of locoregional control and survival, without increasing the incidence of radiation-related toxicities in patients.
机译：在对单一机构的经验的回顾性审查中，研究了Nimotuzumab的长期使用与强度调制的放疗（IMRT）和化疗治疗局部晚期鼻咽癌（NPC）的疗效和安全性。 2008年8月至2014年3月，39例新诊断的阶段DI-IV NPC患者用IMRT，化疗和Nimotuzubab处理。将二十名患者诊断为III期（51.3％），14阶段IVA（35.9％），5阶段IVB（12.8％）疾病。所有患者至少接受了至少一个基于顺铂的诱导化疗的循环，然后在2（x）mg /周下IMRT和超过9周期的Nimotuzumab。根据放射治疗肿瘤学群的急性和晚期放射发病率评分标准进行急性和晚期辐射相关的毒性。根据Kaplan-Meier方法计算累积的存活。日志秩检验用于比较生存差异。中位随访46个月（范围。22-86个月），估计3年局部复发，无左旋转移，无障碍，无失败，以及整体生存率为92.1％分别为89.7％，82.5％，77.6％和86.8％。单变量分析表明，临床阶段和诱导化疗的循环与预后有关。添加Nimotuzumab的中位循环为12周。在15.8％的治疗患者中观察到3级辐射诱导的粘膜炎。没有观察到皮疹或输注反应，与用Nimotuzumab治疗的患者报道的内容明显不同。观察到的主要毒性是I-II粘膜炎和白细胞减少症。长期使用Nimotuzumab Plus IMRT在招生控制和生存方面表现出有希望的结果，而不增加患者辐射相关毒性的发生率。

著录项

  • 来源
    《Oncology Research》 |2018年第2期|共11页
  • 作者

    Wang Fangzheng; Jiang Chuner; Ye Zhiming; Liu Tongxin; Yan Fengqin; Wang Lei; Li Bin; Hu Fujun; Chen Ming; Qin Weifeng; Fu Zhenfu;

  • 作者单位

    Zhejiang Canc Hosp Dept Radiat Oncol 1 Banshan East Rd Hangzhou 310022 Zhejiang Peoples R China;

    Zhejiang Canc Hosp Dept Breast Surg Hangzhou Zhejiang Peoples R China;

    Zhejiang Canc Hosp Dept Radiat Oncol 1 Banshan East Rd Hangzhou 310022 Zhejiang Peoples R China;

    Zhejiang Canc Hosp Dept Radiat Oncol 1 Banshan East Rd Hangzhou 310022 Zhejiang Peoples R China;

    Zhejiang Canc Hosp Dept Radiat Oncol 1 Banshan East Rd Hangzhou 310022 Zhejiang Peoples R China;

    Zhejiang Canc Hosp Dept Radiat Oncol 1 Banshan East Rd Hangzhou 310022 Zhejiang Peoples R China;

    Zhejiang Canc Hosp Dept Radiat Oncol 1 Banshan East Rd Hangzhou 310022 Zhejiang Peoples R China;

    Zhejiang Canc Hosp Dept Radiat Oncol 1 Banshan East Rd Hangzhou 310022 Zhejiang Peoples R China;

    Zhejiang Canc Hosp Dept Radiat Oncol 1 Banshan East Rd Hangzhou 310022 Zhejiang Peoples R China;

    Zhejiang Canc Hosp Dept Radiat Oncol 1 Banshan East Rd Hangzhou 310022 Zhejiang Peoples R China;

    Zhejiang Canc Hosp Dept Radiat Oncol 1 Banshan East Rd Hangzhou 310022 Zhejiang Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

    Nasopharyngeal carcinoma (NPC); Intensity-modulated radiotherapy (IMRT); Nimotuzumab; Prognosis;

    机译：鼻咽癌（NPC）;强度调节放疗（IMRT）;nimotuzumab;预后;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号